Endostar

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Non-small cell lung cancer, in combination with NP (vinorelbine plus cisplatin)... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also approved (1)
CN
  • Non-small cell lung cancer, in combination with NP (vinorelbine plus cisplatin) chemotherapy
Product first approved 2005pmc.ncbi.nlm.nih.gov

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (14)
Non-Small Cell Lung Cancer
NCT02001168 · Xinjiang Medical University
2013-10 – 2022-10 · Non-small Cell Lung Cancer
What this study did
NCT02579564 · Xinqiao Hospital of Chongqing
2016-10 – 2018-12 · Malignant Hydrothorax, Non Small Cell Lung Cancer
What this study did
NCT03008109 · Zaiwen Fan
2017-02 – 2018-11 · Advanced Cancer, Lung Cancer, Nonsmall Cell
What this study did
NCT00576914 · Chinese Academy of Sciences
2007-06 – 2012-06 · Non-small Cell Lung Cancer
What this study did
NCT00657423 · Xijing Hospital
2008-04 – 2009-04 · Lung Neoplasms
What this study did
Other / comorbidity
NCT04914598 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2021-07-28 – 2026-06 · Malignant Pleural Effusion
What this study did
NCT02907710 · First Affiliated Hospital of Guangxi Medical University
2016-10 – 2019-11 · Nasopharyngeal Carcinoma
What this study did
NCT02748772 · The First People's Hospital of Hefei
2016-01 – 2018-12 · Colorectal Neoplasms
What this study did
NCT02865304 · Fujian Cancer Hospital
2016-12 – 2018-12 · Angiogenesis, Breast Cancer
What this study did
NCT01915134 · Zhejiang Cancer Hospital
2013-08 – 2016-12 · Effects of Chemotherapy, Stage IVC Nasopharyngeal Carcinoma
What this study did
NCT02008422 · Tang Xushan
2013-08 – 2016-08 · Gastric Cancer
What this study did
NCT01479036 · Xijing Hospital
2011-10 – 2015-02 · Breast Cancer
What this study did
Phase 2/3 (5)
Non-Small Cell Lung Cancer
NCT03588494 · Affiliated Hospital of North Sichuan Medical College
2018-08-01 – 2021-09-01 · Quality of Life
What this study did
Other / comorbidity
NCT01907529 · Hebei Medical University Fourth Hospital
2019-08 – 2021-12 · Stage III Breast Cancer
What this study did
NCT03577392 · Sichuan Provincial People's Hospital
2018-07-01 – 2021-08-01 · Quality of Life
What this study did
NCT01689558 · Jin Feng
2011-12 – 2017-01 · 1、Enough Cases, 2、Elekta Precise 1343 Digital Control Electron Linear Accelerator, Can Undertake Nasopharyngeal Carcinoma Specimens in the Materia,, Image Department of Nose Pharynx Ministry MRI Dynamic Testing,
What this study did
NCT02350361 · Peking University Third Hospital
2014-01 – 2016-03 · Lung Cancer
What this study did
Phase 2 (90)
Non-Small Cell Lung Cancer
NCT07818304 · The First People's Hospital of Lianyungang
2026-10 – 2028-10 · Non Small Cell Lung Cancer, Lung Neoplasms
What this study did
NCT07841106 · Jiangmen Central Hospital
2026-09-01 – 2028-04-30 · Lung Cancer (Non-Small Cell), Radiation, Brain Injury, Brain Edema, Brain Necrosis
What this study did
NCT06617936 · Hua Zhang
2024-08-27 – 2027-09-10 · Unresectable Non-small Cell Lung Cancer
What this study did
NCT06747169 · Jian-Guo Zhou, MD, PhD
2024-12-17 – 2026-12-17 · Squamous Non-Small Cell Lung Cancer SqNSCLC
What this study did
NCT06618391 · Henan Cancer Hospital
2024-10-08 – 2026-10-30 · Non-small Cell Lung Cancer
What this study did
NCT06279754 · The First Affiliated Hospital of Xinxiang Medical College
2024-02-18 – 2025-12-18 · Locally Advanced Squamous Non-small Cell Lung Cancer
What this study did
NCT06047860 · Second Affiliated Hospital of Soochow University
2023-06-16 – 2024-12-31 · Advanced Solid Tumor, Refractory Tumor
What this study did
NCT05243355 · Qilu Hospital of Shandong University
2021-12-03 – 2024-12-03 · Squamous Non-small Cell Lung Cancer
What this study did
NCT05203276 · The First People's Hospital of Lianyungang
2022-03-01 – 2024-06-30 · Lung Neoplasms
What this study did
NCT05574998 · Qianfoshan Hospital
2021-02-01 – 2024-04-01 · Non-Small-Cell Lung Cancer
What this study did
NCT05448781 · Affiliated Cancer Hospital & Institute of Guangzhou Medical University
2022-07-20 – 2023-12-20 · Non Small Cell Lung Cancer, Endostatin
What this study did
NCT05529355 · Anhui Chest Hospital
2022-09-18 – 2023-09-18 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04094909 · Guangzhou Institute of Respiratory Disease
2020-02-06 – 2023-03-31 · Staging IV NSCLC
What this study did
NCT04303130 · Peking University Cancer Hospital & Institute
2019-12-31 – 2022-12-31 · Non-small Cell Lung Cancer
What this study did
NCT01669707 · Beijing Chest Hospital
2011-04 – 2020-09 · Non-small Cell Lung Cancer
What this study did
NCT03123445 · China Medical University, China
2017-04 – 2019-09 · Non Small Cell Lung Cancer
What this study did
NCT03614065 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2017-02-21 – 2018-11 · Non-small Cell Lung Cancer
What this study did
NCT01549093 · Hunan Province Tumor Hospital
2011-08 – 2016-10 · Non-small Cell Lung Cancer
What this study did
NCT02375022 · Zhejiang University
2015-03 – 2016-03 · Lung Cancer
What this study did
NCT01218594 · Sun Yat-sen University
2009-05 – 2015-12 · Non-small Cell Lung Cancer
What this study did
NCT02005120 · Zhejiang University
2013-12 – 2015-12 · Non Small Cell Lung Cancer
What this study did
NCT01347424 · Sun Yat-sen University
2011-01 – 2014-10 · Non Small Cell Lung Cancer, Nasopharyngeal Cancer, Liver Metastasis
What this study did
NCT01158144 · Zhejiang Cancer Hospital
2009-10 – 2013-12 · Non-small Cell Lung Cancer
What this study did
NCT01564329 · Simcere Pharmaceutical Co., Ltd
2012-03 – 2013-07 · Advanced Primary Lung Adenocarcinoma
What this study did
NCT00708812 · Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
2007-07 – 2009-12 · Advanced Non-small Cell Lung Cancer
What this study did
NCT01687439 · Fudan University
2008-12 – 2009-10 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07794488 · Zhejiang Cancer Hospital
2026-09-01 – 2030-12-30 · Nasopharyngeal Cancinoma (NPC)
What this study did
NCT06611826 · Zhejiang Cancer Hospital
2024-09-30 – 2029-12-30 · Nasopharynx Cancer
What this study did
NCT06965231 · Fudan University
2025-01-01 – 2029-03-30 · Melanoma of Skin, Acral Melanoma, Stage II Melanoma
What this study did
NCT05514275 · Zhejiang Cancer Hospital
2022-08-01 – 2028-08-01 · Nasopharyngeal Carcinoma
What this study did
NCT06055816 · Zhejiang Cancer Hospital
2023-10-24 – 2028-06-30 · Nasopharyngeal Carcinoma
What this study did
NCT06059261 · Chongqing University Cancer Hospital
2026-02-09 – 2027-02-01 · Nasopharyngeal Carcinoma
What this study did
NCT04447326 · First Affiliated Hospital of Guangxi Medical University
2020-06 – 2026-06 · Nasopharyngeal Carcinoma
What this study did
NCT06041724 · Fudan University
2023-09-18 – 2026-03-18 · Advanced Mucosal Melanoma
What this study did
NCT06301828 · Nanjing First Hospital, Nanjing Medical University
2024-02-21 – 2026-02-21 · Gastrointestinal Neoplasms
What this study did
NCT05278715 · Beijing Sanbo Brain Hospital
2022-04-13 – 2025-12-31 · Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma
What this study did
NCT04267978 · Beijing Sanbo Brain Hospital
2020-02-13 – 2025-12-31 · Glioblastoma, Recurrent, Lower Grade Glioma, Recurrent
What this study did
NCT05177237 · Jiangxi Provincial Cancer Hospital
2021-07-28 – 2025-12-30 · Nasopharyngeal Carcinoma
What this study did
NCT05387681 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2022-05-30 – 2025-12-30 · Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy
What this study did
NCT03622827 · Nanjing Medical University
2018-07-31 – 2025-07-30 · Uterine Cervical Neoplasms
What this study did
NCT05385185 · Hebei Medical University
2022-05-01 – 2024-12-03 · Leptomeningeal Metastasis, Immune Checkpoint Inhibitor, Endostatin
What this study did
NCT05907512 · Fudan University
2020-04-01 – 2024-08-31 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT05551247 · First Affiliated Hospital Xi'an Jiaotong University
2022-09-15 – 2024-06-28 · Colorectal Neoplasms
What this study did
NCT03932266 · Jiangsu Cancer Institute & Hospital
2019-06 – 2023-09 · Nasopharyngeal Carcinoma
What this study did
NCT04699214 · Yong Chen
2020-09-01 – 2023-08-31 · Other Disorders of Soft Tissues
What this study did
NCT04659421 · Beijing Sanbo Brain Hospital
2020-11-03 – 2023-07-20 · Low-grade Glioma, Pediatric Brain Tumor
What this study did
NCT04472806 · Fudan University
2020-06-20 – 2023-06-20 · Mucosal Melanoma
What this study did
NCT05298020 · The Affiliated Hospital of Xuzhou Medical University
2022-04-01 – 2023-04-01 · Advanced Pancreatic Cancer
What this study did
NCT02350517 · Yuhong Li
2015-01 – 2022-12 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04121975 · Zhejiang Cancer Hospital
2019-08-01 – 2022-08 · Cervical Cancer
What this study did
Phase 1/2 (2)
Non-Small Cell Lung Cancer
NCT01733589 · Zhejiang Cancer Hospital
2012-11 – 2015-06 · Stage III Non-small-Cell Lung Cancer
What this study did
Other / comorbidity
NCT06562673 · Shanghai 6th People's Hospital
2024-12-03 – 2025-07-20 · Osteosarcoma, Bone Cancer
What this study did
Phase 1 (8)
Non-Small Cell Lung Cancer
NCT04942301 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2021-07-30 – 2022-10-15 · Advanced or Metastatic NSCLC
What this study did
NCT02652234 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2015-08 – 2016-09 · NSCLC
What this study did
NCT01531790 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2011-09 – 2012-12 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT00004872 · University of Wisconsin, Madison
started 2000-03 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01310478 · Fudan University
2010-08 – 2011-05 · Colorectal Neoplasm
What this study did
NCT01260025 · Sun Yat-sen University
2009-09 – 2011-01 · Tolerability, Pharmacokinetics, Endostatin
What this study did
NCT00262327 · Sun Yat-sen University
2005-05 – 2006-02 · Advanced Solid Tumor
What this study did
NCT00004229 · National Cancer Institute (NCI)
1999-10 – 2002-10 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
Phase 4 (11)
Non-Small Cell Lung Cancer
NCT04613284 · Shanghai Chest Hospital
2020-12-01 – 2023-08 · Lung Cancer
What this study did
NCT04356118 · Hui Bu
2020-06 – 2023-06 · Leptomeningeal Metastasis
What this study did
NCT02804646 · Anhui Provincial Hospital
2016-06 – 2018-12 · Adenocarcinoma of Lung
What this study did
NCT02513355 · Nanjing NingQi Medicine Science and Technology Co., Ltd.
2015-02 – 2017-11 · Non-small Cell Lung Cancer
What this study did
NCT02497118 · Tianjin Medical University Cancer Institute and Hospital
2010-08 – 2015-06 · Non Small Cell Lung Cancer
What this study did
NCT01211002 · Simcere Pharmaceutical Co., Ltd
2010-10 – 2012-12 · Non-small Cell Lung Cancer
What this study did
NCT01028729 · Simcere Pharmaceutical Co., Ltd
2009-09 – 2011-08 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT00813332 · Simcere Pharmaceutical Co., Ltd
2008-10 – 2010-10 · Advanced NSCLC, Recurrent NSCLC
What this study did
Other / comorbidity
NCT05782764 · Xuzhou Medical University
2023-06-01 – 2025-05-30 · Lung Squamous Cell Carcinoma
What this study did
NCT04164797 · Second Affiliated Hospital of Xi'an Jiaotong University
2019-11-25 – 2021-07-13 · Patients With Esophageal Cancer(Ⅱ-Ⅲ)
What this study did
NCT02513342 · Nanjing NingQi Medicine Science and Technology Co., Ltd.
2015-03 – 2018-04 · Advanced Lung Squamous Carcinoma
What this study did
Early phase / not applicable (3)
Non-Small Cell Lung Cancer
NCT04063449 · Dong Wang
2019-08-20 – 2021-06-30 · Non-squamous Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT04274270 · Peking University Third Hospital
2020-04-01 – 2023-01-30 · Radiotherapy Side Effect
What this study did
NCT03206957 · Queen Fabiola Children's University Hospital
2017-11-30 – 2019-06-01 · Down Syndrome
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (2)
Other / comorbidity
NCT02636231 · Sun Yat-sen University
2015-11 – 2021-12 · Nasopharyngeal Carcinoma
What this study did
NCT01327235 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2011-03 – 2014-07 · Malignant Pleural Effusion, Malignant Ascites
What this study did

Competitive landscape

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Endostar: this drugPhase 3Protein / enzyme therapeuticVEGFR2 (KDR/Flk-1) on vascular endothelial cellsPartial signal
NCT01124253: OS stage III: NP plus Endostar 41.27m vs NP 39.53m; hazard ratio 1.090 (95% CI 0.627-1.893), Log Rank P = 0.760. Stage I HR 0.952 (0.466-1.946) P = 0.894; stage II HR 0.797 (0.320-1.982) P = 0.625. Median OS not reached in stages I and II. missed
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 550 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Endostar to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-17 · NCT06747169 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-02-01 · NCT06059261 · CT.gov ↗
What to watch
2028 (4)
April 2028 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07818304 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT07841106 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Nasopharynx CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT06611826 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Melanoma of Skin, Acral Melanoma, Stage II MelanomaRecruiting
Est. primary completion 2028-12-30 · NCT06965231 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Nasopharyngeal Cancinoma (NPC)Not yet recruiting
Est. primary completion 2030-12-30 · NCT07794488 · CT.gov ↗
What to watch

See the full readout calendar ↗